KORU Medical Systems Inc

KORU Medical Systems Inc(KRMD)股票分析

$3.030

-0.222 (-7.34%)收盘时

Loading chart…
最高
3.310
开盘
3.310
成交量加权均价
3.09
成交量
143.77K
市值
130.43M
最低
2.920
成交额
443.78K
企业价值/息税折旧摊销前利润(TTM)
36.88

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

AI 分析 of KORU Medical Systems Inc (KRMD)

买入

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

估值指标

KORU Medical Systems Inc(KRMD)当前预期市盈率为 76.34,5 年平均预期市盈率为 -7.42。

预期市盈率

合理
5 年均值 P/E
-7.42
当前P/E
76.34
高估
108.26
低估
-123.09

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-24.07
当前EV/EBITDA
36.88
高估
59.60
低估
-107.75

预期市销率

低估
5 年均值 P/S
4.07
当前P/S
2.53
高估
5.09
低估
3.05

Alphio AI 对 KRMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%KRMD

$3.23

情景价格

基

基准

基准 · 50%KRMD

$2.98

情景价格

悲

悲观

悲观 · 25%KRMD

$2.84

情景价格

持有 KRMD 的大户

F

First Light Asset Management, LLC

+ 持有KRMD

+0.00%

3个月收益率

事件时间线

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

KORU Medical Reports Q4 Revenue of $10.9M

资讯

KRMD 常见问题 —— 由 Alphio AI 解答

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易